Dabigatran
Jump to navigation
Jump to search
In medicine, dabigatran is an anticoagulant that is a direct thrombin inhibitor[1]
In 2009, dabigatran, a direct thrombin inhibitors, was compared to warfarin in the RE-LY randomized controlled trial.[2]
Intervention | Outcomes | ||
---|---|---|---|
Stroke or systemic embolism | Major bleeding | Mortality | |
Dabigatran 110 mg twice daily | 1.53% | 2.71%† | 3.75% |
Dabigatran 150 mg twice daily | 1.11%† | 3.11% | 3.64% |
Warfarin | 1.69% | 3.36% | 4.13% |
† p < 0.05 as compared to warfarin group |
References
- ↑ Anonymous (2024), Dabigatran (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. (2009). "Dabigatran versus Warfarin in Patients with Atrial Fibrillation.". N Engl J Med 361 (12): 1139-1151. DOI:10.1056/NEJMoa0905561. PMID 19717844. Research Blogging.